Reprocell

Reprocell company information, Employees & Contact Information

Explore related pages

Related company profiles:

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

Company Details

Employees
63
Founded
-
Address
8f Kdx Shin-Yokohama 381 Bldg., 3-8-11,shin-Yokohama
Phone
(814) 547-5388
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Yokohama
Looking for a particular Reprocell employee's phone or email?

Reprocell Questions

News

REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF) - PR Newswire

REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF) PR Newswire

REPROCELL announces US FDA drug master file submittal for StemRNA™ clinical iPSC seed clones - Drug Discovery News

REPROCELL announces US FDA drug master file submittal for StemRNA™ clinical iPSC seed clones Drug Discovery News

Regenerative Medicine in Dermatology Market Size, Report by 2034 - Precedence Research

Regenerative Medicine in Dermatology Market Size, Report by 2034 Precedence Research

REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research - BioInformant

REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research BioInformant

How ReproCELL Incorporated (6RC) stock reacts to Fed tightening - Earnings Miss & AI Powered Buy and Sell Recommendations - Trung tâm Dự báo KTTV quốc gia

How ReproCELL Incorporated (6RC) stock reacts to Fed tightening - Earnings Miss & AI Powered Buy and Sell Recommendations Trung tâm Dự báo KTTV quốc gia

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 - Precedence Research

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 Precedence Research

REPROCELL’s Clinical-Grade iPSCs: Advancing Cell Therapy - BioInformant

REPROCELL’s Clinical-Grade iPSCs: Advancing Cell Therapy BioInformant

Reprocell USA secures contract from Lantern to support NSCLC therapy trial - Clinical Trials Arena

Reprocell USA secures contract from Lantern to support NSCLC therapy trial Clinical Trials Arena

Reprocell and JTB commence offering Regenerative Medicine Grade iPS Exosomes|News Room|JTB GROUP SITE - jtbcorp.jp

Reprocell and JTB commence offering Regenerative Medicine Grade iPS Exosomes|News Room|JTB GROUP SITE jtbcorp.jp

REPROCELL : Quotes, Address, Contact - News-Medical

REPROCELL : Quotes, Address, Contact News-Medical

Biopta and Reinnervate to merge to form ReproCELL Europe Ltd - Drug Target Review

Biopta and Reinnervate to merge to form ReproCELL Europe Ltd Drug Target Review

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial - PR Newswire

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial PR Newswire

Reprocell - Durham University

Reprocell Durham University

Why Scotland has a golden future in precision medicine - David Bunton - The Scotsman

Why Scotland has a golden future in precision medicine - David Bunton The Scotsman

How ReproCELL Incorporated (6RC) stock reacts to Fed tightening - Earnings Recap Summary & Daily Entry Point Trade Alerts - Trung tâm Dự báo KTTV quốc gia

How ReproCELL Incorporated (6RC) stock reacts to Fed tightening - Earnings Recap Summary & Daily Entry Point Trade Alerts Trung tâm Dự báo KTTV quốc gia

How higher bond yields impact ReproCELL Incorporated (6RC) stock - 2025 Buyback Activity & Stepwise Trade Execution Plans - Trung tâm Dự báo KTTV quốc gia

How higher bond yields impact ReproCELL Incorporated (6RC) stock - 2025 Buyback Activity & Stepwise Trade Execution Plans Trung tâm Dự báo KTTV quốc gia

Steminent Announces Japan partner ReproCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan - BioInformant

Steminent Announces Japan partner ReproCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan BioInformant

ReproCELL and Steminent Partner to Commercialize Stemchymal in Japan - BioInformant

ReproCELL and Steminent Partner to Commercialize Stemchymal in Japan BioInformant

Group Company Merger Establishes European Headquarters - Labmate Online

Group Company Merger Establishes European Headquarters Labmate Online

Top Reprocell Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant